focus -WSS

focus

author：explore 2025-10-02 09:47:11 - browse：952

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： The problems with dementia villages

WSS

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: The economic case for universal basic health care

Update the Apgar Score to remove skin color

STAT Summit: Ending the crisis of Black deaths in the U.S.

Roche drug slashes death risk in early

Medicare drug price lawsuits could be good politics for Biden

leisure time

focus

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Walensky prepares to leave CDC — and Congress — behind

Prior authorization reform is both possible and imperative

Alkermes shareholders re

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Apple is now the first public company to be valued at $3 trillion

FDA endorses new sterilization method for medical devices

In Memoriam: Notable people who died in 2023

Dog Aging Project founders on what lies ahead after losing funding

hotspot

STAT Summit: The economic case for universal basic health care

Maisha Meds is a PBM, but don't call it that

Cardiologists urge adding sexual orientation, gender identity to health records

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

High breast density mammograms need follow

leisure time

hotspot

explore

Wikipedia